From: Prevalence of ESR1 E380Q mutation in tumor tissue and plasma from Japanese breast cancer patients
No. of patients (%) | ||
---|---|---|
PBC | MBC | |
Variables | (N = 9) | (N = 57) |
Age at biopsy | ||
Median (range) | 56 (31–68) | 58 (31–95) |
Primary clinical stage | ||
I | 2 (22.2) | 22 (38.6) |
II | 6 (66.7) | 17 (29.8) |
III | 1 (11.1) | 8 (14) |
IV | 0 | 10 (17.5) |
Histological type | ||
Invasive ductal | 9 (100) | 53 (93) |
Invasive lobular | 0 | 3 (5.3) |
Mucinous | 0 | 1 (1.8) |
Histological grade | ||
1 | 6 (66.7) | 10 (17.5) |
2 | 2 (22.2) | 27 (47.4) |
3 | 1 (11.1) | 17 (29.8) |
Lobular | 0 | 3 (5.2) |
Median percentage of ERα (25%, 75%) | 90 (75, 92.5) | 85 (70, 90) |
Median percentage of PgR (25%, 75%) | 10 (5, 45) | 30 (5, 60) |
HER2 | ||
Positive | 0 | 5 (8.7) |
Negative | 9 (100) | 52 (91.2) |
Presence of ESR1 LBD mutations | ||
Yes | 0 | 11 (19.3) |
No | 9 (100) | 46 (80.7) |
Number of metastatic organs | ||
Median (range) | 2 (1–5) | |
Visceral involvement | ||
Yes | 28 (49.1) | |
No | 29 (50.9) | |
Metastatic lesions biopsied | ||
Breast | 9 (15.8) | |
Skin | 19 (33.3) | |
Lymph Nodes | 14 (24.6) | |
Bone | 4 (7.0) | |
Lung | 3 (5.2) | |
Liver | 4 (7.0) | |
Brain | 3 (5.2) | |
Ovary | 1 (1.8) | |
Number of rounds of prior endocrine therapy | ||
Median (range) | 2 (0–6) | |
Number of rounds of prior chemotherapy | ||
Median (range) | 0 (0–6) |